CN113853382A - 新型肽及其用途 - Google Patents

新型肽及其用途 Download PDF

Info

Publication number
CN113853382A
CN113853382A CN202080017996.0A CN202080017996A CN113853382A CN 113853382 A CN113853382 A CN 113853382A CN 202080017996 A CN202080017996 A CN 202080017996A CN 113853382 A CN113853382 A CN 113853382A
Authority
CN
China
Prior art keywords
peptide
amyloid
disease
peptides
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080017996.0A
Other languages
English (en)
Chinese (zh)
Inventor
纳兹尼恩·德维基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Senna Biosciences
Original Assignee
Senna Biosciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senna Biosciences filed Critical Senna Biosciences
Priority to CN202210033802.7A priority Critical patent/CN114437173A/zh
Publication of CN113853382A publication Critical patent/CN113853382A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CN202080017996.0A 2019-01-07 2020-01-06 新型肽及其用途 Pending CN113853382A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210033802.7A CN114437173A (zh) 2019-01-07 2020-01-06 新型肽及其用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962789114P 2019-01-07 2019-01-07
US62/789,114 2019-01-07
PCT/US2020/012323 WO2020146236A1 (en) 2019-01-07 2020-01-06 Novel peptides and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210033802.7A Division CN114437173A (zh) 2019-01-07 2020-01-06 新型肽及其用途

Publications (1)

Publication Number Publication Date
CN113853382A true CN113853382A (zh) 2021-12-28

Family

ID=71520880

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080017996.0A Pending CN113853382A (zh) 2019-01-07 2020-01-06 新型肽及其用途
CN202210033802.7A Pending CN114437173A (zh) 2019-01-07 2020-01-06 新型肽及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202210033802.7A Pending CN114437173A (zh) 2019-01-07 2020-01-06 新型肽及其用途

Country Status (9)

Country Link
US (1) US20220064214A1 (https=)
EP (1) EP3908307A4 (https=)
JP (2) JP2022516574A (https=)
KR (1) KR20220004618A (https=)
CN (2) CN113853382A (https=)
AU (2) AU2020207203A1 (https=)
CA (1) CA3125552A1 (https=)
IL (1) IL284666A (https=)
WO (1) WO2020146236A1 (https=)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4966848A (en) * 1988-02-08 1990-10-30 The General Hospital Corporation Isolation, purification, characterization, cloning and sequencing of N α-acetyltransferase
US5223421A (en) * 1989-10-25 1993-06-29 The General Hospital Corporation Identification of methionine Nα-acetyltransferase
US5688489A (en) * 1995-09-15 1997-11-18 Resolution Pharmaceuticals, Inc. Non-receptor mediated imaging agents
US6777388B1 (en) * 1998-08-21 2004-08-17 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US20030077740A1 (en) * 2001-03-05 2003-04-24 Schubert David R. Presenilin/Crk binding polypeptides (PCBP) and methods of use thereof
US8129334B2 (en) * 2006-03-31 2012-03-06 The Regents Of The University Of California Methods and compositions for treating neurodegenerative disorders and Alzheimer'S disease and improving normal memory
JP2013526518A (ja) * 2010-05-13 2013-06-24 ザ ユニバーシティ オブ ケンタッキー リサーチ ファウンデーション Ｍｃｉおよびアルツハイマー病の処置
CN106456799B (zh) * 2014-06-03 2020-05-22 江苏佳瑞生物技术有限公司 肽-药物偶联物

Also Published As

Publication number Publication date
EP3908307A1 (en) 2021-11-17
CA3125552A1 (en) 2020-07-16
JP2022516574A (ja) 2022-02-28
EP3908307A4 (en) 2022-10-12
CN114437173A (zh) 2022-05-06
IL284666A (en) 2021-08-31
JP2025041635A (ja) 2025-03-26
AU2026200229A1 (en) 2026-02-05
US20220064214A1 (en) 2022-03-03
AU2020207203A1 (en) 2021-08-19
KR20220004618A (ko) 2022-01-11
WO2020146236A1 (en) 2020-07-16

Similar Documents

Publication Publication Date Title
KR102285378B1 (ko) 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체의 지속형 결합체
CN107921085B (zh) 用于治疗衰老相关病症的方法和组合物
CN103476933B (zh) 白介素1受体的拮抗剂
CN108138150B (zh) 细胞透性改善的(iCP)帕金重组蛋白及其用途
KR20220130678A (ko) 프로그라눌린 변이체들
US8530416B2 (en) Variants of pigment epithelium derived factor and uses thereof
CN103648517A (zh) 神经保护肽
JP2006505243A (ja) Ｍｃｐタンパク質の新規のアンタゴニスト
AU2020409569B2 (en) Retro-inverso peptides
KR20210116559A (ko) 중추신경계 질환의 치료 방법
WO2021133907A1 (en) Progranulin variants
JPWO2008038599A1 (ja) 軸索再生促進剤
JP2009519006A (ja) 改善された色素上皮由来因子変異体及びその使用
CN113853382A (zh) 新型肽及其用途
JP2009504689A (ja) Ｇｄｎｆ由来ペプチド
US20170137483A1 (en) Use of epo-derived peptide fragments for the treatment of inflammatory diseases
WO2014061772A1 (ja) 新規ｎｋ３受容体アゴニスト
WO2024192296A1 (en) Compositions and methods for treating alzheimer's disease
HK40084870A (en) Biological macromolecular target-specific complement inhibitor, preparation method therefor, and application thereof
WO2014161095A1 (en) Crp40 fragments for the treatment of neurological disorders

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination